Michelle A. Baron - Concepedia

Author

Michelle A. Baron

Novartis (United States)ORCID

Also Known As

M. A. Baron, M. Baron, M.A. Baron, MICHELLE A. BARON, Michelle A Baron, Michelle A. Baron, Michelle Baron

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Novartis (United States)Novartis (Switzerland)Dallas Diabetes Research Center Intarcia Therapeutics (United States)Tris Pharma (United States)

About

Michelle A. Baron is an author at Novartis (United States) specializing in diabetes, medicine, and metabolic syndrome.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	646
2	Diabetes	5	5	646
3	Health Sciences	1	1	21
4	Public Health	1	1	85
5	Endocrinology	1	1	367

Michelle A. Baron

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes Vivian Fonseca, Anja Schweizer, Diego Albrecht, Diabetologia Metabolic SyndromeDiabetes ManagementImproves Glycaemic ControlMedicineInsulin Management	2007	367
Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes Julio Rosenstock, Michelle A. Baron, S. Dejager, Diabetes Care	2007	271
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo‐controlled study* A. J. Garber, Anja Schweizer, Michelle A. Baron, Diabetes Obesity and Metabolism	2006	268
Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes Julio Rosenstock, S. W Kim, Michelle A. Baron, Diabetes Obesity and Metabolism	2007	258
Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea* A. J. Garber, James E. Foley, Mary Ann Banerji, Diabetes Obesity and Metabolism	2008	232
Effects of the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin on Incretin Hormones, Islet Function, and Postprandial Glycemia in Subjects With Impaired Glucose Tolerance Julio Rosenstock, James E. Foley, Marc Rendell, Diabetes Care	2007	154
PRESERVE-β John E. Gerich, Philip Raskin, Lisa Jean-Louis, Diabetes Care	2005	115
Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial Christian T. Ruff, Michelle A. Baron, KyungAh Im, Nature Medicine Diabetes ManagementCardiovascular DiseaseCardiovascular OutcomesDiabetesType 2	2021	91
Impact of comorbid conditions and race/ethnicity on glycemic control among the US population with type 2 diabetes, 1988–1994 to 1999–2004 Dong‐Churl Suh, In‐Sun Choi, Craig Plauschinat, Journal of Diabetes and its Complications Diabetes ManagementHealth Care DisparityDiabetes EpidemiologyHealth PolicyGlobal Health	2009	85
Sustained Efficacy and Reduced Hypoglycemia during One Year of Treatment with Vildagliptin Added to Insulin in Patients with Type 2 Diabetes Mellitus Vivian Fonseca, Michelle A. Baron, Q. Shao, Hormone and Metabolic Research Metabolic SyndromeDiabetes ManagementDrug-naïve PatientsInsulin ManagementDiabetes	2008	82

Page 1